Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation (FLR) by Berger Montague on behalf of investors who acquired shares between February 18, 2025, and July 31, 2025, due to alleged misrepresentation of the company's financial condition and undisclosed issues with major infrastructure projects [1][3]. Company Overview - Fluor Corporation, headquartered in Irving, Texas, provides engineering, procurement, construction, and project management services globally, with its Urban Solutions segment being the largest revenue contributor [2]. Allegations and Investigation - The investigation focuses on claims that FLR misrepresented its financial health and concealed rising costs and delays in key infrastructure projects, specifically the Gordie Howe, I-635/LBJ, and I-35 projects, which are vital to its Urban Solutions segment [3]. Financial Performance - On August 1, 2025, FLR reported disappointing Q2 2025 results, with earnings per share (EPS) of $0.43 and revenue of $3.98 billion, missing consensus estimates by $0.13 and $570 million, respectively. The company also reduced its full-year forecast, attributing the shortfall to project execution failures and a slowdown in new contract awards. Following this announcement, FLR's stock price fell over 27%, closing at $41.42 on the same day [4]. Market Reaction - In the wake of the disappointing results, several brokerages downgraded FLR's stock, citing significant concerns regarding the company's internal controls and transparency [5].

Core Viewpoint - A class action lawsuit has been filed against KBR, Inc. by Berger Montague on behalf of investors who acquired KBR shares between May 6, 2025, and June 19, 2025, due to undisclosed concerns regarding a key military contract [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that KBR failed to disclose material concerns from the U.S. Department of Defense's Transportation Command (TRANSCOM) regarding HomeSafe's ability to fulfill the Global Household Goods Contract [3]. - KBR reassured investors that the contract would proceed as expected, despite being aware of the issues within the partnership [3]. - Following the disclosure of the contract termination by HomeSafe on June 19, 2025, KBR's shares dropped by $3.85, or 7%, closing at $48.93 on June 20, 2025 [4]. Group 2: Company Background - KBR, Inc. is a Houston-based firm specializing in engineering, technology, and government services, providing logistics and operations support to various federal agencies, including the Department of Defense [2].

PHILADELPHIA , Sept. 23, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC  announces a class action lawsuit against Sable Offshore Corp. (NYSE: SOC) ("Sable" or the "Company") on behalf of investors who purchased or otherwise acquired publicly traded securities of Sable between May 19, 2025 through June 3, 2025 (the "Class Period"), including on or traceable to the Company's May 2025 secondary public offering. ...

PHILADELPHIA , Sept. 22, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC  announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise acquired publicly traded securities of Altimmune between August 10, 2023 through June 25, 2025 (the "Class Period"). ...

Group 1 - A class action lawsuit has been announced against Fluor Corporation by Berger Montague PC on behalf of investors [1] - The lawsuit pertains to investors who purchased or acquired shares during the period from February 18, 2025, through July 31, 2025 [1]

Core Viewpoint - Berger Montague PC is investigating potential securities fraud claims against Fiserv, Inc. following a class action lawsuit filed on behalf of investors who acquired Fiserv securities between July 24, 2024, and July 22, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit alleges that Fiserv and certain executives overstated the Company's growth by failing to disclose that its new payment platform, Clover, was experiencing increased revenue growth and gross payment volumes due to the forced transition of merchants from its legacy Payeezy platform [3]. - Investors became aware of the true financial situation of Fiserv after a series of disclosures, culminating on July 23, 2025, when the Company lowered its 2025 organic growth projections and confirmed decelerated growth in its Merchant segment [4]. Group 2: Investor Information - Investors who purchased or acquired Fiserv securities during the Class Period have until September 22, 2025, to seek appointment as a lead plaintiff representative of the class [2].

Core Viewpoint - National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. for misleading statements made during the Class Period from March 17, 2022, to September 22, 2022 [1][3] Company Overview - Spectrum Pharmaceuticals is a biopharmaceutical company focused on oncology treatments [2] Legal Proceedings - A class action lawsuit has been filed alleging that Spectrum made false or misleading statements regarding its Pinnacle Study, which involved the drug poziotinib for lung cancer treatment [3] - Investors who acquired Spectrum securities during the Class Period have until September 24, 2025, to seek appointment as lead plaintiff representative [2] Contact Information - Investors seeking more information can contact Andrew Abramowitz or Caitlin Adorni at Berger Montague [4][6]

Core Viewpoint - A class action lawsuit has been filed against KinderCare Learning Companies, Inc. for allegedly misleading investors during its IPO period, particularly regarding the quality of care provided at its facilities [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased shares from October 6, 2024, to August 12, 2025, including during the October 2024 IPO [1][2]. - Investors have until October 14, 2025, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations - The investigation centers on claims that the IPO registration statement contained false and misleading information, failing to disclose incidents of child abuse and neglect at KinderCare facilities [3]. - It is alleged that KinderCare did not meet minimum care standards or legal compliance requirements, contradicting claims of providing "the highest quality care possible" [3]. Group 3: Financial Impact - Since the IPO, KinderCare's shares have significantly declined, reaching lows near $9 per share, resulting in substantial losses for investors [4].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its business and financial outlook, leading to a significant drop in share price [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased LifeMD shares between May 7, 2025, and August 5, 2025 [1][2]. - Investors have until October 27, 2025, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations Against LifeMD - LifeMD is accused of overstating its competitive position and raising its 2025 guidance without properly accounting for increasing customer acquisition costs, particularly in its RexMD segment and for obesity-related drugs [3]. - Following the revelation of the true facts, LifeMD's shares plummeted by 44%, equating to a decrease of $5.31 per share in a single trading session [3].

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc. following a class action lawsuit filed on behalf of investors who acquired RxSight securities during the specified Class Period [1][2]. Company Overview - RxSight, Inc. is a medical technology company based in Aliso Viejo, CA, specializing in light adjustable intraocular lenses (LAL) used in cataract surgery, with its system involving the Light Delivery Device (LDD) [2]. Legal Allegations - The lawsuit alleges that RxSight's management failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. The CEO attributed the sales stall to adoption challenges [4]. - Following this announcement, RxSight's shares dropped by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].